Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Cash (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Change in Cash for 6 consecutive years, with -$28.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 1779.37% to -$28.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$139.0 million, a 57.69% decrease, with the full-year FY2024 number at -$99.8 million, down 150.71% from a year prior.
  • Change in Cash was -$28.6 million for Q3 2025 at 4D Molecular Therapeutics, up from -$56.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $157.7 million in Q2 2023 to a low of -$152.8 million in Q3 2021.
  • A 5-year average of -$12.0 million and a median of -$16.1 million in 2021 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: skyrocketed 859.1% in 2023, then crashed 1779.37% in 2025.
  • 4D Molecular Therapeutics' Change in Cash stood at $62.0 million in 2021, then plummeted by 190.22% to -$55.9 million in 2022, then surged by 52.51% to -$26.6 million in 2023, then tumbled by 43.78% to -$38.2 million in 2024, then increased by 25.13% to -$28.6 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Change in Cash are -$28.6 million (Q3 2025), -$56.4 million (Q2 2025), and -$15.8 million (Q1 2025).